Pharmacology of locus coeruleus spontaneous and sensory-evoked activity.
Neuroendocrine and catecholamine dysfunctions in depression may be linked by corticotropin-releasing factor (CRF) effects on locus coeruleus (LC) neurons. One consequence of CRF hypersecretion in depression would be persistent elevated levels of LC discharge and diminished responses to phasic sensory stimuli. The hypothesis that antidepressants could reverse these changes was tested by characterizing effects of pharmacologically distinct antidepressants on LC sensory-evoked discharge, LC activation by stress, and LC activation by CRF. The most consistent effect of all of the antidepressants tested was a decrease in LC sensory-evoked discharge after acute administration. However, tolerance occurs to these effects after chronic administration. With chronic administration each of the antidepressants produced effects which could potentially interfere with CRF function in the LC. Desmethylimipramine and mianserin attenuated LC activation by a stressor which requires endogenous CRF, suggesting that these antidepressants attenuate stress-elicited release of CRF and perhaps the hypersecretion that occurs in depression. The serotonin reuptake inhibitor, sertraline (SER), enhanced the signal-to-noise ratio of the LC sensory response, an effect opposite to that of CRF. Thus, SER could serve as a functional antagonist of CRF that is hypersecreted in depression. The finding that three pharmacologically distinct antidepressants share the potential to interfere with CRF function in the LC implies that this may be an important common mechanism for antidepressant activity.
Valentino
R J
RJ
Department of Mental Health Science, Hahnemann University, Philadelphia, PA.
Curtis
A L
AL
D015057:1-Naphthylamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000928:Antidepressive Agents / Q000145:classification / Q000494:pharmacology*; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology*; D003863:Depression / Q000503:physiopathology; D003864:Depression, Chemical; D003891:Desipramine / Q000494:pharmacology; D004361:Drug Tolerance; D004597:Electroshock; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D008125:Locus Coeruleus / Q000187:drug effects* / Q000502:physiology; D008803:Mianserin / Q000494:pharmacology; D009599:Nitroprusside / Q000494:pharmacology; D010146:Pain / Q000503:physiopathology; D051381:Rats; D020280:Sertraline; D013312:Stress, Physiological / Q000503:physiopathology
D000928:Antidepressive Agents; D009599:Nitroprusside; D008803:Mianserin; D003346:Corticotropin-Releasing Hormone; D015057:1-Naphthylamine; D020280:Sertraline; D003891:Desipramine